Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$85.05 USD
+1.09 (1.30%)
Updated May 31, 2024 04:00 PM ET
After-Market: $85.19 +0.14 (0.16%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Ligand Pharmaceuticals Incorporated [LGND]
Reports for Purchase
Showing records 221 - 240 ( 717 total )
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
VDP Platform Visibility Increasing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Late Stage Asset Added to the Mix; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
1Q19 Recap - LT Outlook Should Outweigh ST Pipeline Setbacks
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
1Q19 Results Running on All Pistons; Target Reduced to $214
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Kyprolis Continues Its Blocking and Tackling; Plethora of Partnered Drivers Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Zulresso Approved; New Revenue Stream Coming; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Model Update - Base Business Better than Expected
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
We''re Repeating Ourselves: Follow the Track Record, Numbers and Growth Prospects; Analyst Day Highlights
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Ligand Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Major Chess Move Announced and Chunk of Change Coming In; Target Reduced to $254
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J